Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
Claire N. Harrison, Alessandro M. Vannucchi, Uwe Platzbecker, Francisco Cervantes, Vikas Gupta, David Lavie, Francesco Passamonti, Elliott F. Winton, Hua Dong, Jun Kawashima, Julia D. Maltzman, Jean Jacques Kiladjian, Srdan Verstovsek
Dive into the research topics of 'Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial'. Together they form a unique fingerprint.